Literature DB >> 9773428

Biliary atresia: pathogenesis and treatment.

M D Bates1, J C Bucuvalas, M H Alonso, F C Ryckman.   

Abstract

Biliary atresia is a disorder of infants in which there is obliteration or discontinuity of the extrahepatic biliary system, resulting in obstruction of bile flow. Untreated, the resulting cholestasis leads to progressive conjugated hyperbilirubinemia, cirrhosis, and hepatic failure. Biliary atresia has an incidence of approximately one in 10,000 live births worldwide. Evidence to date supports a number of pathogenic mechanisms for the development of biliary atresia. An infectious cause, such as by a virus, would seem most pausible in many cases. The clinical observation that biliary atresia is rarely encountered in premature infants would support an agent acting late in gestation. However, no infectious or toxic agent has been conclusively implicated in biliary atresia. Genetic mechanisms likely play important roles, even regarding susceptibility to other specific causes, but no gene whose altered function would result in obstruction or atresia of the biliary tree has been identified. The variety of clinical presentations support the notion that the proposed mechanisms are not mutually exclusive but may play roles individually or in combination in certain patients. Biliary atresia, when untreated, is fatal within 2 years, with a median survival of 8 months. The natural history of biliary atresia has been favorably altered by the Kasai portoenterostomy. Approximately 25 to 35% of patients who undergo a Kasai portoenterostomy will survive more than 10 years without liver transplantation. One third of the patients drain bile but develop complications of cirrhosis and require liver transplantation before age 10. For the remaining one third of patients, bile flow is inadequate following portoenterostomy and the children develop progressive fibrosis and cirrhosis. The portoenterostomy should be done before there is irreversible sclerosis of the intrahepatic bile ducts. Consequently, a prompt evaluation is indicated for any infant older than 14 days with jaundice to determine if conjugated hyperbilirubinemia is present. If infectious, metabolic, endocrine disorders are unlikely and if the child has findings consistent with biliary atresia, then exploratory laparotomy and intraoperative cholangiogram should be done expeditiously by a surgeon who has experience doing the Kasai portoenteostomy. Biliary atresia represents the most common indication for pediatric liver transplantation, representing more than 50% of cases in most series. Transplantation is indicated when symptoms of end stage liver disease occur, including recurrent cholangitis, progressive jaundice, portal hypertension complications, ascites, decreased synthetic function, and growth/nutritional failure.

Entities:  

Mesh:

Year:  1998        PMID: 9773428     DOI: 10.1055/s-2007-1007164

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  22 in total

1.  Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Authors:  Indsey Kennedy; Heather Francis; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  Liver Res       Date:  2017-04-26

Review 2.  Liver fibrosis in biliary atresia.

Authors:  Wen-Jun Shen; Gong Chen; Min Wang; Shan Zheng
Journal:  World J Pediatr       Date:  2018-11-21       Impact factor: 2.764

3.  Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia.

Authors:  Wataru Sumida; Hiroo Uchida; Takahisa Tainaka; Chiyoe Shirota; Akinari Hinoki; Takazumi Kato; Kazuki Yokota; Kazuo Oshima; Ryo Shirotuki; Kosuke Chiba; Yujiro Tanaka
Journal:  Pediatr Surg Int       Date:  2018-07-28       Impact factor: 1.827

Review 4.  Left-right patterning in congenital heart disease beyond heterotaxy.

Authors:  George C Gabriel; Cecilia W Lo
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-01-30       Impact factor: 3.908

5.  Liver and portal histopathological correlation with age and survival in extra hepatic biliary atresia.

Authors:  Shilpa Sharma; Prasenjit Das; S Dattagupta; Lalit Kumar; Devendra K Gupta
Journal:  Pediatr Surg Int       Date:  2011-05       Impact factor: 1.827

6.  Therapeutic effects of vitamin A on experimental cholestatic rats with hepatic fibrosis.

Authors:  Ken-ichi Murakami; Tatsuru Kaji; Ryuichi Shimono; Yoshihiro Hayashida; Hiroshi Matsufuji; Shinichiro Tsuyama; Rie Maezono; Ken-ichiro Kosai; Hideo Takamatsu
Journal:  Pediatr Surg Int       Date:  2011-02-03       Impact factor: 1.827

7.  Ultrasonic diagnosis of biliary atresia: a retrospective analysis of 20 patients.

Authors:  Shi-Xing Li; Yao Zhang; Mei Sun; Bo Shi; Zhong-Yi Xu; Ying Huang; Zhi-Qin Mao
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

8.  Should open Kasai portoenterostomy be performed for biliary atresia in the era of laparoscopy?

Authors:  Kenneth K Y Wong; Patrick H Y Chung; Kwong-Leung Chan; Sheung-Tat Fan; Paul K H Tam
Journal:  Pediatr Surg Int       Date:  2008-06-28       Impact factor: 1.827

Review 9.  [Cholestasis-associated hepatopathies in neonates and infants].

Authors:  G Knöpfle; A Adam; H-P Fischer
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

10.  Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary disease.

Authors:  Erik S Barton; Bryan E Youree; Daniel H Ebert; J Craig Forrest; Jodi L Connolly; Tibor Valyi-Nagy; Kay Washington; J Denise Wetzel; Terence S Dermody
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.